Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06160466
Other study ID # NP4451
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 16, 2020
Est. completion date May 1, 2024

Study information

Verified date February 2024
Source Fondazione Poliambulanza Istituto Ospedaliero
Contact Daniele Salvi
Phone 0303515373
Email daniele.salvi@poliambulanza.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the diagnostic yield of CADe in a consecutive population undergoing colonoscopy. The main question it aims to answer is the Adenoma Detection Rate (ADR). Participants undergoing colonoscopy for follow-up in a screening setting will be randomized in a 1:1 ratio to either receive Computer-Aided Detection (CADe) colonoscopy or a conventional colonoscopy (CC). GI Genius is the AI software that will be used in the present trial and is intended to be used as an adjunct to colonic endoscopy procedures to help endoscopists to detect in real time mucosal lesions (such as polyps and adenomas, including those with flat (non-polypoid) morphology) during standard screening and surveillance endoscopic mucosal evaluations. It is not intended to replace histopathological sampling as a means of diagnosis.Researchers will compare the CADe group and the CC-group to see if CAD-e can increase the ADR significantly.


Description:

en if colonoscopy is considered the reference standard for the detection of colonic neoplasia, polyps are still missed. In large administrative cohort or case-control studies, the risk of early post-colonoscopy cancer appeared to be independently predicted by a relatively low polyp/adenoma detection rate. The adenoma detection rate among different endoscopists has been shown to be strictly related with the risk of post-colonoscopy interval cancer. When considering the very high prevalence of advanced neoplasia in the FIT-positive enriched population, the risk of post-colonoscopy interval cancer due to a suboptimal quality of colonoscopy may be substantial. Available evidence justifies therefore the implementation of efforts aimed at improving adenoma detection rate, based on retraining interventions and on the adoption of innovative technologies, designed to enhance the accuracy of the endoscopic examination.Nowadays, Artificial intelligence (AI) is gaining increased attention and investigation, since it seems to improve the quality of medical diagnosis and treatment. In the field of gastrointestinal endoscopy, two potential roles of AI in colonoscopy have been examined so far: automated polyp detection (CADe) and automated polyp histology characterization (CADx). CADe can minimize the probability of missing a polyp during colonoscopy, thereby improving the adenoma detection rate (ADR) and potentially decreasing the incidence of interval cancer. GI Genius is the AI software that will be used in the present trial. The software is developed by Medtronic Inc. (Dublin, Ireland) and is intended to be used as an adjunct to colonic endoscopy procedures to help endoscopists to detect in real time mucosal lesions (such as polyps and adenomas, including those with flat (non-polypoid) morphology) during standard screening and surveillance endoscopic mucosal evaluations. It is not intended to replace histopathological sampling as a means of diagnosis. The objective of this study was to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC). As the risk of progression is higher for large than for small adenomas the specific contribution of the new technique in reducing the miss rate of large neoplasms represents an important outcome to be assessed in the study. In addition, given the suggested association of a higher miss-rate of serrated and flat lesions with an increased risk of early post-colonoscopy CRC, the benefit of the new technique in reducing the miss rate of these lesions will be assessed.


Recruitment information / eligibility

Status Recruiting
Enrollment 1160
Est. completion date May 1, 2024
Est. primary completion date March 1, 2024
Accepts healthy volunteers No
Gender All
Age group 50 Years to 74 Years
Eligibility Inclusion Criteria: - Patients aged 50 to 74 undergoing colonoscopy examination following a prior colonsocopy were polyps were found (follow-up) performed in the context of a regional mass-screening program. Exclusion Criteria: - Patients unwilling or unable to give informed consent. - Patients reporting use of anti-platelet agents or anticoagulants precluding removal of polyps.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CADe colonoscopy using GI Genius device
We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a follow-up pateints in the screening population.
White light
White light endoscopy

Locations

Country Name City State
Italy Fondazione Poliambulanza Brescia Bs

Sponsors (1)

Lead Sponsor Collaborator
Fondazione Poliambulanza Istituto Ospedaliero

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of advanced adenomas The percentage of patients with adenomas with high-grade displasia in CADe colonoscopy group will be recorded and compared with the rate of patients with adenomas with high-grade displasia in standard colonoscopy group. When available the histological report of polyps removed (up to 3 weeks).
Primary Rate of patients detected with 3 or more adenomas. The percentage of patients with 3 or more adenomas (serrated adenomas will also be considered in the calculation) in CADe colonoscopy group will be compared with the rate of patients with 3 or more adenomas (including serrated adenomas) in standard colonoscopy group. When available the histological report of polyps removed (up to 3 weeks).
Secondary Overall adenoma and polyp detection rate, flat adenoma and serrated polyps/adenomas. The percentage of adenomas, polyps (in general), flat adenoma and serrated polyps/adenoma detected will be recorded and compared between the groups. When available the histological report of polyps removed (up to 3 weeks).
Secondary Size of lesions detected The size of lesion detected will be measured in millimiters and compared between the groups. Immediately after the procedure.
Secondary Rate of neoplasia by colonic site The percentage of patients with neoplasia of proximal (right colonic segments) or distal (left colonic segments and rectum) site will be assessed and compared between the groups. Immediately after the procedure.
Secondary Post-colonoscopy surveilance the time interval, expressed in years, to the next suggested follow-up colonoscopy will be assessed and compared between the groups. When available the histological report of polyps removed (up to 3 weeks).
Secondary Time of cecal intubation. The time to reach the cecum will be measured in minutes, recorded and compared between the groups. Immediately after the procedure.
Secondary Withdrawal and total procedure time. The time of withdrawal (from cecum to anus) and of the overall colonoscopy (from anus to anus) will be measured in minutes, recorded and compared between the groups. Immediately after the procedure.
Secondary Learning curve. The above-mentioned outcomes will be calculated for each endoscopist at 3, 6, 9 and 12 months. 3, 6, 9 and 12 months.
Secondary Specific contribution of AI Proportion of patients diagnosed with polyps which were detected only by Artificial intelligence Immediately after the procedure.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT02545699 - Prospective Trial to Compare ADR of G-EYE™ Colonoscopy With Standard Colonoscopy N/A
Completed NCT01802008 - Comparison of Adenoma Detection Miss Rates at Colonoscopy Associated With Different Withdrawal Times N/A
Recruiting NCT01211132 - Cap Assisted Colonoscopy for the Detection of Colon Polyps N/A
Completed NCT04287335 - Multitarget Stool FIT-DNA Study for Colorectal Cancer Early Screening in China
Not yet recruiting NCT06398418 - R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors Phase 1
Recruiting NCT05362344 - Colorectal Cancer Screening in Cystic Fibrosis
Completed NCT03268200 - The Effect of Segmental Re-examination of Colon for Adenoma Detection in Colonoscopy N/A
Recruiting NCT04591145 - Multi-center Validation of a Deep Learning Based Bowel Preparation Evaluation System
Completed NCT02978664 - The Impact of Distraction on Adenoma Detection Rate N/A
Completed NCT00018551 - Chemoprevention With Folic Acid Phase 2
Recruiting NCT05594576 - Comparison of the ENDOCUFF VISION® Endoscopy Cap Coupled With GI GENIUS™ Artificial Intelligence Compared to Each Device Alone in Improving Colonic Adenoma Detection Rate During Colonoscopy N/A
Not yet recruiting NCT04135716 - A Multicenter Study Evaluating the Effectiveness of Endo.Angel in Improving the Quality of Colonoscopy N/A
Recruiting NCT02288962 - Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Phase 3
Recruiting NCT02552017 - Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities N/A
Completed NCT02066064 - G-Eye Advanced Colonoscopy For Increased Polyp Detection Rate-randomized Tandem Study With Different Endoscopist N/A
Completed NCT01749722 - Safety and Efficacy of the NaviAid™ G-Eye System During Colonoscopy N/A
Completed NCT01485133 - Water Method Colonoscopy in Patients With Prior Surgery N/A
Withdrawn NCT01546220 - Water Method in Elder Patients With Unsedated Colonoscopy N/A
Withdrawn NCT01546259 - Water Method in Low-body Mass Index (BMI) Female Patients With Unsedated Colonoscopy N/A